Harrow (HROW) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

$0.13

Estimate

$0.30

Surprise

-56.9%

Revenue (period 2026-09-30)

$99.3M

Score today

5.5/10

Revenue source: xbrl.

Harrow (HROW) missed the $0.30 estimate with adjusted EPS of $0.13 — a large 56.9% shortfall.

• AAON, Ziprecruiter, Rackspace Technology, Babcock & Wilcox And Other Big Stocks Moving Higher On Tuesday — benzinga, 2026-11-10
• Harrow Q3 2026 Earnings Call Transcript — benzinga, 2026-11-10
• 12 Health Care Stocks Moving In Tuesday's Pre-Market Session — benzinga, 2026-11-10

TrendMatrix currently rates HROW Sell at 5.5/10; no pre/post engine snapshot brackets this report.

0 of the last 4 quarters beat the estimate; this quarter's -56.9% surprise compares with a -79.1% four-quarter average.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$31.40

Price target

$54.81

Stop

$29.20

Upside to target

+74.6%

Reward-to-risk

5.0:1

Model outputs from TrendMatrix’s engine as of 2026-11-10 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Drug Manufacturers - Specialty & Generic

Market cap

$1.03B

P/E (fwd)

10.7

52-week range

$25.76–$54.85

Off 52-week high

42.8%

RSI (14)

63

Volume vs avg

1.98×

Score today

5.5/10